Divalproex Sodium Tablet, Delayed Release
Product Images NDC 55154-2336

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55154-2336). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (5e59609f D79d 414b A6fc 7efb1ba5b200 00)

Label for Divalproex Sodium delayed-release tablets USP 500 mg, 10 count. The label includes NDC 55154-2336-0 and directions for storage (20 to 25 °C, excursions allowed to 15 to 30 °C). It notes the product contains valproic acid equivalent to 500 mg and is for oral use, prescription only. Manufactured by Sun Pharmaceutical Industries Ltd, distributed by Cardinal Health 107, LLC among others. The label instructs pharmacists to dispense with medication guide.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A bar chart labeled Figure 1 comparing percentages for placebo (PBO) and Divalproex Sodium (DVPX) in two studies: Study 1 (YMRS) and Study 2 (MRS). The chart shows higher percentages for DVPX (60%, 58%) compared to PBO (26%, 29%) in both studies.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A cumulative percentage plot comparing the percentage reduction in CPS rate among patients using Divalproex Sodium (DVPX) versus placebo. The y-axis represents the percentage reduction in CPS rate from -100% (worsening) to 100% (improvement), and the x-axis shows the cumulative percentage of patients from 100% to 0%. Solid line corresponds to Divalproex Sodium and dashed line to placebo, illustrating the treatment effect distribution.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A cumulative distribution plot showing the percentage reduction in CPS rate for patients taking high and low doses of a drug. The x-axis represents the percentage of patients, decreasing from 100 to 0, and the y-axis shows the reduction in CPS rate from -100% to 100%. Two lines depict results for high dose (solid line) and low dose (dashed line) groups, with an annotation indicating improvement, no change, and worsening directions on the right side.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates for Placebo and Divalproex Sodium (DVPX) groups across two studies. The vertical axis measures migraine rates from 0 to 6, showing lower mean migraine rates in DVPX groups compared to Placebo in both Study 1 and Study 2.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure of Divalproex Sodium showing the arrangement of carbon, hydrogen, oxygen, and sodium atoms in its molecular form, including branched alkyl chains and carboxylate groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.